National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines Committee
for Use of Tumor Markers in Clinical Practice: Quality Requirements
These include all reported relationships within the previous 2 years that may be relevant to the guidelines document.
|
|
|
Grant |
Other Research Support |
Speakers Bureau |
Honoraria |
Expert Witness |
Ownership Interest |
Consultant Advisory Board |
Institution Employer |
Other Disclosures |
|
Sturgeon |
Significant (>$10K)/Other |
None |
None |
None |
Abbott Diagnostics; Bayer Diagnostics; Beckman Coulter; Becton Dickinson; DAKO Ltd; DPC; Roche; Tosoh Biosciences Ltd; Wallac Oy Ltd |
None |
None |
None |
None |
None |
|
Diamandis |
Significant (>$10K)/Other |
None |
None |
None |
None |
None |
None |
None |
None |
None |
|
Hoffman |
Significant (>$10K)/Other |
None |
None |
None |
None |
None |
None |
None |
None |
None |
|
Chan |
Significant (>$10K)/Other |
None |
Abbott; Beckman |
Ciphergen; Roche |
None |
None |
None |
None |
None |
Tosoh (consulting) |
|
Ling Ch’ng |
Significant (>$10K)/Other |
None
|
None |
None |
None |
None |
None |
None |
None |
None |
|
Hammond |
Significant (>$10K)/Other |
None |
None |
None |
None |
None |
None |
None |
None |
None |
|
Hayes |
Significant (>$10K) |
None |
None |
None |
None |
None |
None |
None |
None |
None |
|
|
Other (less than 10K) |
None |
Immunicon; Glaxo Smith Kline; Wyeth Ayerst Genetics Institute; Pfizer; Novartis |
None |
None |
None |
None |
Abraxis; American Biosciences; AviaraDx; Cytogen Corp; Monogram Bioscience; Pfizer; Precision Therapeutics Inc; Prudential Financial; QuatRx Pharm; Siemens Medical Solutions Diagnostics; SternCapture |
None |
None |
|
Liotta |
Significant (>$10K)/Other |
None |
None |
None |
None |
None |
None |
Theranostics Health |
None |
None |
|
Petricoin |
Significant (>$10K)/Other |
None |
None |
None |
None |
None |
None |
None |
None |
None |
|
Schmitt |
Significant (>$10K)/Other |
None |
American Diagnostics Inc; Epigenomics AG |
None |
None |
None |
None |
None |
None |
None |
|
Semmes |
Significant (>$10K)/Other |
None |
None |
None |
None |
None |
None |
None |
None |
None |
|
Sölétormos |
Significant (>$10K)/Other |
None |
None |
None |
None |
None |
None |
None |
None |
None |
|
Merwe |
Significant (>$10K)/Other |
None |
None |
None |
None |
None |
None |
None |
None |
None |